Why measure three antibody classes (IgM, IgG, IgA) instead of one?

IgM appears early in acute infection, IgG rises later and persists for years, and IgA reflects mucosal involvement and may signal chronic or recurrent infection. The three-class profile improves differentiation of acute, past, and possible chronic states.

Does a positive IgG result mean the patient has active infection?

No. A single positive IgG indicates past exposure — up to half of adults have detectable IgG from prior infection. Active disease requires a fourfold rise in IgG between paired samples two to four weeks apart, or clinical correlation with IgM and IgA.

When should paired acute and convalescent samples be collected?

Collect the acute sample at symptom onset and the convalescent sample two to four weeks later. Testing both in parallel demonstrates seroconversion or rising titre, the serological hallmark of recent infection.

Can this test cross-react with other Chlamydia species?

Yes. Shared epitopes among C. pneumoniae, C. trachomatis, and C. psittaci can cause cross-reactivity, particularly for IgM. Species-specific confirmation may be needed in equivocal or discordant cases.

Is fasting required for the test?

No. Antibody serology does not require fasting and can be collected at any time of day.

What is the clinical significance of elevated IgA?

Elevated IgA reflects mucosal immune activation and may indicate active respiratory involvement or chronic infection. In research contexts IgA has been linked to atherosclerotic inflammation and chronic lung disease, though clinical consensus is evolving.

Why is serology the primary diagnostic method for C. pneumoniae?

Culture is technically demanding and slow, and polymerase chain reaction is not widely available. Serology is accessible and, when interpreted with paired samples and clinical context, provides reliable evidence of infection.

How long do results take?

Results are typically available within 5–10 business days from specimen receipt at Access Medical Laboratories, longer if confirmation or batch testing is required.

BML-AUT-020autoimmune inflammationUSA

Chlamydophila pneumoniae Antibodies (IgM, IgG, IgA)

The C. pneumoniae antibodies panel measures IgM, IgG, and IgA responses to an obligate intracellular respiratory pathogen responsible for atypical pneumonia and bronchitis. Serology differentiates acute infection (rising IgG, early IgM) from past exposure (persistent IgG) and possible chronic carriage (elevated IgA), though high population seroprevalence and assay variability require paired…

Biomarkers

Blood (serum)

Sample

5–10 business days

Turnaround

Fasting

What is the C. pneumoniae Abs test?

The Chlamydophila pneumoniae Antibodies panel measures IgM, IgG, and IgA responses to an obligate intracellular bacterium responsible for community-acquired pneumonia, bronchitis, and pharyngitis. C. pneumoniae is transmitted person to person via respiratory droplets and is distinct from C. trachomatis and C. psittaci. Serology is the mainstay of diagnosis because culture is technically demanding and polymerase chain reaction is not widely available outside specialist laboratories. Practitioners order this panel to confirm suspected atypical pneumonia when clinical and radiological findings suggest bacterial rather than viral aetiology, to investigate prolonged respiratory symptoms that have not responded to beta-lactam antibiotics, and in research or functional-medicine settings to explore associations between chronic C. pneumoniae exposure and conditions such as atherosclerosis, reactive arthritis, and asthma exacerbation. The three-class antibody profile allows differentiation of acute infection, past exposure, and possible chronic carriage, though interpretation is nuanced by high population seroprevalence and variable assay performance.

What does the C. pneumoniae Abs test measure?

C. pneumoniae IgM(Chlamydophila pneumoniae IgM Antibody)

Range: Negative <0.90; Equivocal 0.90–1.10; Positive >1.10 (index values, assay-dependent).Optimal: Negative index value (<0.90) in the absence of recent respiratory infection.Index value / titre

IgM antibodies appear within one to two weeks of acute Chlamydophila pneumoniae infection and typically decline over the following months. They reflect early immune response to the organism's lipopolysaccharide and major outer-membrane protein epitopes. Because IgM can persist at low levels in chronic or recurrent infection and cross-react with other Chlamydia species, interpretation requires clinical correlation and consideration of the IgG and IgA profiles.

Elevated IgM suggests recent or acute infection, though isolated IgM positivity is less specific than a rising IgG titre. Serial sampling and examination of all three immunoglobulin classes improve diagnostic confidence, particularly in respiratory presentations where C. pneumoniae is one of several atypical pathogens.

C. pneumoniae IgG(Chlamydophila pneumoniae IgG Antibody)

Range: Negative <0.90; Equivocal 0.90–1.10; Positive >1.10 (index values, assay-dependent).Optimal: Negative or low-positive index consistent with resolved past exposure and absence of active infection.Index value / titre

IgG antibodies to C. pneumoniae appear later than IgM, typically several weeks into infection, and can persist for years after resolution. The organism is highly prevalent, so a substantial proportion of adults harbour detectable IgG from prior asymptomatic or mildly symptomatic exposure. Rising titres between acute and convalescent sera are the traditional serological hallmark of acute infection.

A single elevated IgG titre indicates past exposure but does not confirm active disease. A fourfold rise in IgG between paired samples two to four weeks apart is strong evidence of recent infection. Persistent high IgG, especially with elevated IgA, has been explored as a marker of chronic or smouldering infection in cardiovascular and autoimmune research, though clinical consensus remains evolving.

C. pneumoniae IgA(Chlamydophila pneumoniae IgA Antibody)

Range: Negative <0.90; Equivocal 0.90–1.10; Positive >1.10 (index values, assay-dependent).Optimal: Negative index value in the absence of active respiratory or systemic inflammation.Index value / titre

IgA antibodies to C. pneumoniae reflect mucosal immune activation and can be elevated in both acute respiratory infection and in chronic or recurrent states. IgA may persist longer than IgM after resolution of symptoms, and its presence alongside IgG has been proposed as a serological signature of chronic infection or reactivation, though the evidence for this remains contested.

Elevated IgA supports active or recent mucosal involvement. In research contexts IgA has been associated with atherosclerotic plaque inflammation and chronic respiratory conditions, prompting its inclusion in three-class antibody panels. Interpretation must account for the limited specificity of IgA and the high background seroprevalence of C. pneumoniae.

Why is the C. pneumoniae Abs test ordered?

Investigation of community-acquired pneumonia or atypical pneumonia syndrome with negative routine bacterial cultures, particularly when macrolide therapy is being considered
Prolonged or recurrent respiratory symptoms — persistent cough, wheeze, or pharyngitis — in patients who have not responded to first-line beta-lactam antibiotics
Serological work-up of suspected atypical pathogens (alongside Mycoplasma pneumoniae and Legionella) in outbreak or public-health contexts
Evaluation of reactive arthritis or other post-infectious inflammatory sequelae following respiratory illness
Functional-medicine assessment of chronic inflammatory states, cardiovascular risk, or autoimmune conditions where chronic intracellular infection is part of the differential or therapeutic hypothesis
Paired acute and convalescent serology (two to four weeks apart) to document seroconversion or rising titre in clinically suspected cases
Research protocols examining the role of persistent C. pneumoniae in atherosclerosis, chronic obstructive pulmonary disease, or asthma pathogenesis

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

5–10 business days

Collection notes

Phlebotomy at the patient service centre; serum is separated and forwarded to Access Medical Laboratories. For optimal diagnostic sensitivity collect an acute sample at symptom onset and a convalescent sample two to four weeks later to document seroconversion or fourfold titre rise. No special preparation required.

Specimen requirements

Minimum 1 mL serum per sample. Store refrigerated if not processed immediately; stable for up to one week refrigerated, longer frozen. Paired acute and convalescent sera should be tested in parallel to reduce inter-assay variability.

What can affect C. pneumoniae Abs results?

elevatesCross-reactivity with other Chlamydia species

Shared epitopes among C. pneumoniae, C. trachomatis, and C. psittaci can cause false-positive or difficult-to-interpret results, particularly for IgM; species-specific confirmation may require specialised reference assays.

variableHigh background seroprevalence

Up to half of adults have detectable IgG from past asymptomatic infection, so a single positive IgG does not establish causality for current symptoms; paired sera are needed to demonstrate a rising titre.

reducesImmunosuppression or early sampling

Antibody responses may be blunted or delayed in immunocompromised patients and in very early infection (first week), leading to false-negative serology; repeat testing after two weeks improves sensitivity.

variablePersistent low-level antibodies in chronic or recurrent infection

Some individuals maintain detectable IgM or elevated IgA long after symptom resolution, complicating the distinction between acute, chronic, and resolved infection without paired samples or clinical correlation.

variableAssay variability and lack of standardisation

Enzyme immunoassays, microimmunofluorescence, and other platforms use different antigens and cut-offs; results are not directly comparable across methods, and microimmunofluorescence is considered more specific but less widely available.

What do C. pneumoniae Abs results mean?

Elevated

A positive IgM suggests recent or acute Chlamydophila pneumoniae infection, though IgM may be absent in reinfection; a fourfold rise in IgG across paired acute and convalescent sera is the most reliable indicator of acute infection. Elevated IgA has been proposed as a marker of chronic or persistent infection but is not well standardised. Single elevated IgG reflects past exposure, which is common in the general population.

Normal

Negative IgM and IgA with a stable low IgG indicate no serological evidence of recent or active infection. Serology is supportive and is best interpreted with paired sera and the clinical picture rather than from a single specimen.

Reduced

Low or negative titres reduce the likelihood of recent infection but do not exclude very early infection before seroconversion. Because background IgG seroprevalence is high in adults, a negative IgG in an adult is relatively uncommon and, when present, argues against prior exposure.

Note: C. pneumoniae serology is poorly standardised across platforms and single-sample results are difficult to interpret; paired acute and convalescent sera are preferred. High background IgG seroprevalence limits the value of a single IgG. The clinical significance of IgA and of chronic-infection interpretations is contested.

Frequently asked questions

C. pneumoniae is an obligate intracellular bacterium spread person to person via respiratory droplets. It causes community-acquired pneumonia, bronchitis, and pharyngitis and is distinct from C. trachomatis and C. psittaci.

How to access the C. pneumoniae Abs test

The C. pneumoniae Abs reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Blasi F, et al. Chlamydophila pneumoniae. Clin Microbiol Infect. (2009)
Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J. (2000)
Dowell SF, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. (2001)
Sessa R, et al. Microimmunofluorescence and enzyme immunoassay tests for detection of antibodies to Chlamydia pneumoniae. J Clin Microbiol. (1998)
Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. (2000)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.